Prasco Laboratories has signed a marketing and distribution agreement with Eli Lilly and Co. to market an authorized generic version of Evista tablets (raloxifene hydrochloride 60 mg) in the United States.


Prasco Laboratories, Evista, authorized generic, raloxifene hydrochloride, Eli Lilly, David Vucurevich, osteoporosis in postmenopausal women




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Prasco rolls out Evista authorized generic

April 1st, 2014

CINCINNATI – Prasco Laboratories has signed a marketing and distribution agreement with Eli Lilly and Co. to market an authorized generic version of Evista tablets (raloxifene hydrochloride 60 mg) in the United States.

Financial terms of the agreement weren't disclosed. The company said Tuesday that it plans to start shipping the product immediately.

Evista is an estrogen agonist/antagonist indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and lower the risk of invasive breast cancer in postmenopausal women at a high risk for invasive breast cancer.

"Evista represents our third Eli Lilly and Co. authorized generic product launched, and we are very pleased to broaden that relationship," stated David Vucurevich, president and chief operating officer of Prasco.

"Prasco's authorized generic products ensure consistent supply to customers and pharmacists. Additionally, our authorized generic products allow patients to continue their therapy using the same brand with which they are accustomed, but at a generic cost savings," he added.

Advertisement